Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 8/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.35 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | ARG1 | P05089 | 1/20 | 0.33 |
| ▸ | ARG2 | P78540 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25660783 | 0.94 | ALDH1A1 (0.36) | FOLH1KDM4EALDH1A1NOD1MEN1 | |
| SCHEMBL17642082 | 0.85 | KISS1R (0.36) | FOLH1KDM4EALDH1A1SMN1; SMN2ITGB3 | |
| SCHEMBL15315080 | 0.85 | KISS1R (0.36) | FOLH1KDM4EALDH1A1SMN1; SMN2ITGB3 | |
| SCHEMBL13262513 | 0.85 | FOLH1 (0.40) | FOLH1KDM4EALDH1A1NOD1SMN1; SMN2 | |
| SCHEMBL25132732 | 0.84 | KDM4E (0.35) | KDM4EALDH1A1ITGB3ITGA2BNPSR1 | |
| SCHEMBL22309224 | 0.84 | FOLH1 (0.39) | FOLH1KDM4EALDH1A1NOD1SMN1; SMN2 | |
| SCHEMBL24225804 | 0.84 | FOLH1 (0.42) | FOLH1KDM4EALDH1A1NOD1SMN1; SMN2 | |
| SCHEMBL434550 | 0.82 | CPB2 (0.43) | FOLH1NOD1SMN1; SMN2 | |
| SCHEMBL19401625 | 0.82 | CPB2 (0.43) | FOLH1NOD1SMN1; SMN2 | |
| SCHEMBL13057114 | 0.82 | CPB2 (0.43) | FOLH1NOD1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024052333-A1 | MULTIVALENT FIBROBLAST ACTIVATION PROTEIN LIGANDS FOR TARGETED DELIVERY APPLICATIONS | PHILOCHEM AG (CH) | 2024-03-14 | — | — | WO | disclosed |
| WO-2023144379-A1 | HIGH-AFFINITY LIGANDS OF FIBROBLAST ACTIVATION PROTEIN FOR TARGETED DELIVERY APPLICATIONS | PHILOCHEM AG (CH) | 2023-08-03 | — | — | WO | disclosed |
| US-20220144889-A1 | Hemiasterlin Derivative Having Cysteine Residue | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-05-12 | — | — | US | disclosed |
| US-20210340222-A1 | HYBRID IMMUNOGLOBULIN CONTAINING NONPEPTIDYL LINKAGE | BIOMOLECULAR HOLDINGS LLC (US) | 2021-11-04 | — | — | US | disclosed |
| US-20170008950-A1 | HYBRID IMMUNOGLOBULIN CONTAINING NON-PEPTIDYL LINKAGE | BIOMOLECULAR HOLDINGS LLC | 2017-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144889-A1 | Hemiasterlin Derivative Having Cysteine Residue | SHBG, CYP11A1, CYP11B1 | FOLH1 2813/4885KDM4E 4517/4885ALDH1A1 1627/4885 |
| US-20210340222-A1 | HYBRID IMMUNOGLOBULIN CONTAINING NONPEPTIDYL LINKAGE | FCGR3B, FCGR2A, SCLY | FOLH1 245/4885KDM4E 4367/4885ALDH1A1 3577/4885 |
| US-20170008950-A1 | HYBRID IMMUNOGLOBULIN CONTAINING NON-PEPTIDYL LINKAGE | FCGR3B, SCLY, FCGR2A | FOLH1 352/4885KDM4E 4315/4885ALDH1A1 4426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.